Cargando…

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective

The therapeutic administration of subcutaneous immunoglobulin (SCIg) offers various advantages over intravenous immunoglobulin (IVIg). This narrative review examines and compares SCIg versus IVIg in chronic inflammatory demyelinating polyneuropathy (CIDP). SCIg is as effective as IVIg but is better...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cocito, Dario, Peci, Erdita, Torrieri, Maria Claudia, Clerico, Marinella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671960/ https://www.ncbi.nlm.nih.gov/pubmed/38002576 http://dx.doi.org/10.3390/jcm12226961

Ejemplares similares

Peripheral Nerve Ultrasonography in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: Correlations with Clinical and Neurophysiological Data
por: Merola, Aristide, et al.
Publicado: (2016)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy
por: Markvardsen, Lars K., et al.
Publicado: (2023)

Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report
por: Cianci, Paola, et al.
Publicado: (2019)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis
por: Hiya, Satomi, et al.
Publicado: (2022)

Neurophysiological Correlates in Patients with Syringomyelia and Chiari Malformation: The Cortico-Diaphragmatic Involvement
por: Cocito, Dario, et al.
Publicado: (2022)

Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis
por: Perraudin, Clémence, et al.
Publicado: (2020)

Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
por: Alsolaihim, Alanood, et al.
Publicado: (2020)

Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
por: Mahdi-Rogers, Mohamed, et al.
Publicado: (2010)

Evolving Immunologic Perspectives in Chronic Inflammatory Demyelinating Polyneuropathy
por: Rajabally, Yusuf A, et al.
Publicado: (2020)

Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain
por: Cocito, Dario, et al.
Publicado: (2014)

Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Merkies, Ingemar S. J., et al.
Publicado: (2022)

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial
por: van Schaik, Ivo N., et al.
Publicado: (2016)

Depression with Chronic Inflammatory Demyelinating Polyneuropathy
por: Marwale, Arun, et al.
Publicado: (2018)

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Khoo, Anthony, et al.
Publicado: (2019)

Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins
por: Finsterer, Josef, et al.
Publicado: (2017)

Clinical and Neurophysiological Follow-Up of Chronic Inflammatory Demyelinating Polyneuropathy Patients Treated with Subcutaneous Immunoglobulins: A Real-Life Single Center Study
por: Alonge, Paolo, et al.
Publicado: (2022)

Tailoring of therapy for chronic inflammatory demyelinating polyneuropathy
por: Rajabally, Yusuf A.
Publicado: (2015)

Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy
por: Allen, Jeffrey A., et al.
Publicado: (2018)

The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy
por: Bril, Vera, et al.
Publicado: (2016)

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
por: Tortorici, Michael A., et al.
Publicado: (2021)

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023)

Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy
por: Rajabally, Yusuf A., et al.
Publicado: (2018)

IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV
por: Reghukumar, Aravind, et al.
Publicado: (2014)

Chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus
por: Fatehi, Farzad, et al.
Publicado: (2013)

Fibrillary glomerulonephritis combined with chronic inflammatory demyelinating polyneuropathy
por: Sung, Woo Kyung, et al.
Publicado: (2015)

Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy
por: Stettner, Mark, et al.
Publicado: (2015)

Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy
por: Chaudhary, Umair J., et al.
Publicado: (2020)

Peripheral Nerve Enlargement in Chronic Inflammatory Demyelinating Polyneuropathy
por: Tanitame, Keizo, et al.
Publicado: (2020)

Nerve Ultrasound Score in Chronic Inflammatory Demyelinating Polyneuropathy
por: Tan, Cheng-Yin, et al.
Publicado: (2023)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US
por: Guptill, Jeffrey T, et al.
Publicado: (2019)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy
por: Graf, Jonas, et al.
Publicado: (2018)

Bilateral optic neuritis related to chronic inflammatory demyelinating polyneuropathy
por: Lin, Kui-Yueh, et al.
Publicado: (2015)

The Prevalence and Severity of Autonomic Dysfunction in Chronic Inflammatory Demyelinating Polyneuropathy
por: Pasangulapati, Suresh Babu, et al.
Publicado: (2017)

Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
por: Belmokhtar, Chafké, et al.
Publicado: (2019)

Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19
por: Abu-Rumeileh, Samir, et al.
Publicado: (2020)

COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy
por: Van Looy, Eveline, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7md6ghljb8lm6amliavi11qg9t